Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p.VGI.1 (VEGF2) Gene Transfer for Diabetic Neuropathy
NCT00056290Phase 2Completed
- Start
- Dec 2002
- Primary completion
- Apr 2008
- Countries
- 1
01
Overview
Phase 2, randomised trial in diabetic neuropathy comparing VEGF with Placebo (2 arms). Primary endpoint: Safety at 6 months. Started Dec 2002; status: completed.
02
Drugs
vascular endothelial growth factor
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT00056290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056290.